المؤلفون: Fakih, Marwan, Prager, M.D., Gerald, Van Cutsem, Eric, Tabernero, Josep, taieb, julien, Ciardiello, Fortunato

المساهمون: Institut Català de la Salut, Tabernero J Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Taieb J Georges Pompidou European Hospital, AP-HP, Paris-Cité University, SIRIC CARPEM Comprehensive Cancer Center, Paris, France. Fakih M City of Hope Comprehensive Cancer Center, Duarte, USA. Prager GW Department of Medicine I, Medical University of Vienna, Vienna, Austria. Van Cutsem E University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium. Ciardiello F University of Campania Luigi Vanvitelli, Naples, Italy, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Anomalies cromosòmiques, Recte - Càncer - Tractament, Còlon - Càncer - Tractament, Quimioteràpia combinada, PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation, DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada

وصف الملف: application/pdf

العلاقة: ESMO Open;9(3); https://doi.org/10.1016/j.esmoop.2024.102945Test; Tabernero J, Taieb J, Fakih M, Prager GW, Van Cutsem E, Ciardiello F, et al. Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial. ESMO Open. 2024 Mar;9(3):102945.; https://hdl.handle.net/11351/11212Test

الإتاحة: https://doi.org/10.1016/j.esmoop.2024.102945Test
https://hdl.handle.net/11351/11212Test

المؤلفون: Bokemeyer, Carsten, Dubreuil , Olivier, GUIGAY, Joel, Kasper, Stefan, Pfeiffer, Per, Ciardiello, Fortunato, Tabernero, Josep

المساهمون: Institut Català de la Salut, Bokemeyer C The II Medical Clinic, Department of Oncology, Hematology & BMT with section of Pneumology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany. Ciardiello F Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. Dubreuil O Medical Oncology Unit, Diaconesses-Croix St Simon Hospital, Paris, France. Guigay J Groupe d’Oncologie Radiothérapie Tête Et Cou (GORTEC), Tours, France. Kasper S Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. Pfeiffer P Department of Oncology, Odense University Hospital, Odense, Denmark. Tabernero J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Càncer - Tractament, Anticossos monoclonals - Ús terapèutic, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal, Other subheadings::Other subheadings::/therapeutic use, DISEASES::Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales, Otros calificadores::Otros calificadores::/uso terapéutico, ENFERMEDADES::neoplasias, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia

وصف الملف: application/pdf

العلاقة: Future Oncology;20(7); https://doi.org/10.2217/fon-2023-0282Test; Bokemeyer C, Ciardiello F, Dubreuil O, Guigay J, Kasper S, Pfeiffer P, et al. Cetuximab every 2 weeks versus standard weekly dosing administration schedule. Futur Oncol. 2024 Mar;20(7):393–407.; https://hdl.handle.net/11351/11209Test; 001087969000001

الإتاحة: https://doi.org/10.2217/fon-2023-0282Test
https://hdl.handle.net/11351/11209Test

المؤلفون: Ciardiello, Fortunato, Hirsch, Fred R., Pirker, Robert, Valencia, Christian, Smit, Egbert, FELIP, ENRIQUETA

المساهمون: Institut Català de la Salut, Ciardiello F Department of Precision Medicine, The University of Campania Luigi Vanvitelli, Naples, Italy. Hirsch FR Center for Thoracic Oncology, Tisch Cancer Institute at Mount Sinai, New York, NY, USA. Pirker R Private Practice for Internal Medicine (Hemato-Oncology), Vienna, Austria. Felip E Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Valencia C EMD Serono Research & Development Institute, Inc, Billerica, MA, USA. Smit EF Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, the Netherlands, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Anticossos monoclonals - Ús terapèutic, Pulmons - Càncer - Tractament, Anomalies cromosòmiques, Proteïnes quinases - Inhibidors - Ús terapèutic, DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung, Other subheadings::Other subheadings::Other subheadings::/drug therapy, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal, PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales, FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas

وصف الملف: application/pdf

العلاقة: Cancer Treatment Reviews;122; https://doi.org/10.1016/j.ctrv.2023.102664Test; Ciardiello F, Hirsch FR, Pirker R, Felip E, Valencia C, Smit EF. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer. Cancer Treat Rev. 2024 Jan;122:102664.; https://hdl.handle.net/11351/10974Test; 001135624600001

الإتاحة: https://doi.org/10.1016/j.ctrv.2023.102664Test
https://hdl.handle.net/11351/10974Test

المؤلفون: Ciardiello, Davide, Martini, Giulia, Napolitano, Stefania, Tabernero Caturla, Josep, Cervantes, Andrés, Ciardiello, Fortunato

المساهمون: Institut Català de la Salut, Ciardiello F, Martini G, Napolitano S Division of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. Ciardiello D Division of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. Division of Medical Oncology, IRCCS Foundation Home for the Relief of Suffering, San Giovanni Rotondo, Italy. Tabernero J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Institute of Oncology, University of Vic/Central University of Catalonia, Barcelona, Spain. Oncology Institute of BarcelonaQuironsalud, Biomedical Research Center in Cancer, Barcelona, Spain. Cervantes A Medical Oncology Department, Instituto de Investigación Sanitaria Valencia Biomedical Research Institute, University of Valencia, Valencia Spain. Carlos III Institute of Health, Biomedical Research Center in Cancer, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Còlon - Càncer - Tractament, Recte - Càncer - Tractament, Medicina personalitzada, DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms, Other subheadings::Other subheadings::/therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Precision Medicine, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales, Otros calificadores::Otros calificadores::/terapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::medicina de precisión

وصف الملف: application/pdf

العلاقة: CA: A Cancer Journal for Clinicians;72(4); https://doi.org/10.3322/caac.21728Test; Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022 Jul;72(4):372–401.; https://hdl.handle.net/11351/8137Test; 000787357900001

الإتاحة: https://doi.org/10.3322/caac.21728Test
https://hdl.handle.net/11351/8137Test

المؤلفون: Tabernero Caturla, Josep, Prager, Gerald W, Leger, Catherine, Fakih, Marwan, Taieb, Julien, Ciardiello, Fortunato

المساهمون: Institut Català de la Salut, Tabernero J Vall d'Hebron Hospital Universitari, Barcelona, Spain. Institute of Oncology (VHIO), Barcelona, Spain. Taieb J Service d'hépatogastroentérologie et d'oncologie digestive, Université de Paris, Paris Descartes University, Georges Pompidou European Hospital, 20 rue Leblanc, Paris, France. Prager GW Department of Medicine I, Comprehensive Cancer Centre Vienna, Medical University Vienna, Josefstaedter Str. 23/15, Vienna, Austria. Ciardiello F Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Via S. Pansini, Naples, Italy. Fakih M Briskin Center for Clinical Research, Section Head and GI Medical Oncology, City of Hope Comprehensive Cancer Center, 1500 E Duarte St, Duarte, CA, USA. Leger C Institut de Recherches Internationales Servier, 50 rue Carnot, Suresnes Cedex, France, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Medicaments antineoplàstics - Ús terapèutic, Recte - Càncer, Còlon - Càncer, DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols, Other subheadings::Other subheadings::/therapeutic use, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinada, Otros calificadores::Otros calificadores::/uso terapéutico

وصف الملف: application/pdf

العلاقة: Future Oncology;17(16); Tabernero J, Taieb J, Prager GW, Ciardiello F, Fakih M, Leger C, et al. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. Futur Oncol. 2021 Jun;17(16):1977–1985.; https://hdl.handle.net/11351/6146Test; 000616966800001

الإتاحة: https://doi.org/10.2217/fon-2020-1238Test
https://hdl.handle.net/11351/6146Test